EMA Authorised: Kivexa (abacavir;lamivudine) — ViiV Healthcare BV

View source ↗

Summary

The European Medicines Agency authorised Kivexa, a fixed-dose combination of abacavir and lamivudine, for HIV infections. ViiV Healthcare BV is the marketing au…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Kivexa (abacavir/lamivudine)

Snippet

Status: Authorised. Therapeutic area: HIV Infections. MAH: ViiV Healthcare BV. Decision date: 15/01/2026